Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

339.79 -1.92 (-0.56%)

Streaming Delayed Price Updated: 9:36 AM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

60 61 Next >

Growth At Any Price (GAAP) Is A Bad Strategy. Valuation Matters. ↗

September 08, 2024

The current leadership in the stock market is clearly not tech, or the Magnificent 7.

Via Talk Markets

Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern ↗

September 05, 2024

Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.

Via Benzinga

Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗

September 03, 2024

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...

Via Benzinga

Topics Economy

(AMGN) - Analyzing Amgen's Short Interest ↗

September 03, 2024

Via Benzinga

Amgen Unusual Options Activity For August 29 ↗

August 29, 2024

Via Benzinga

Smart Money Is Betting Big In AMGN Options ↗

August 12, 2024

Via Benzinga

Amgen Options Trading: A Deep Dive into Market Sentiment ↗

August 08, 2024

Via Benzinga

Patchy But Still Bullish ↗

September 02, 2024

Two weeks ago we turned to a more bullish stance, which has proved to be correct, though we still await the explosive movement out of these consolidations.

Via Talk Markets

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades' ↗

August 29, 2024

Jason Snipe of Odyssey Capital Advisors likes Intuit Inc., after the company beat on the top and bottom lines, but missed on guidance.

Via Benzinga

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug ↗

August 27, 2024

The single-dose vials will also increase supply, the drug giant says.

Via Investor's Business Daily

Eli Lilly’s Path to the Next Trillion Market Capitalization

August 26, 2024

Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.

Via MarketBeat

3 Unstoppable Dividend Stocks to Buy Right Now ↗

August 25, 2024

These stocks are the A-team for income investors.

Via The Motley Fool

US Stocks May Take a Breather After S&P 500's Impressive 8-Session Winning Streak: Strategist Says Market Will Hit Fresh Highs In Next 4 Weeks, But Warns Investors Of Potential Risks ↗

August 20, 2024

The gravity-defying climb faces risk, as the index futures trade narrowly mixed in early trading on Tuesday. That said, the recent gains could keep traders wary of a potential pullback.

Via Benzinga

Topics Stocks

ProInvestor Insights - August 2024 ↗

August 19, 2024

Our August newletter features insights from high-level Wall Street researchers, traders, analysts, and economists that you won’t find anywhere else. And AAII’s first-to-be-seen interview with legendary...

Via Talk Markets

2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade ↗

August 18, 2024

Investors seeking reliable dividend growth want to start with these two members of the Dow Jones Industrial Average.

Via The Motley Fool

Topics Stocks

This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline ↗

August 17, 2024

Amgen has many growth opportunities ahead, and it also pays a fairly high dividend.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2024

Via Benzinga

Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations ↗

August 15, 2024

The unveiled prices follow months of back-and-forth negotiation between the government and the companies.

Via Investor's Business Daily

MarketBeat Week in Review – 8/5 - 8/9

August 10, 2024

Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings

Via MarketBeat

Topics Economy

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗

August 09, 2024

After Monday's panicked global sell-off, markets have calmed down.

Via Investor's Business Daily

The Defensive Sectors And VIX Have NOT Given The All-Clear Signal ↗

August 08, 2024

The market has been a rollercoaster lately, with the resilience of defensive sectors and the modest bounce in the technology sector painting an intriguing picture.

Via Talk Markets

Topics Stocks

Here's Why Eli Lilly Stock Dropped 12% Last Month ↗

August 08, 2024

News from a competitor gave investors an unwelcome dose of reality.

Via The Motley Fool

Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts ↗

August 07, 2024

Amgen posted mixed Q2 results. Analysts highlight upcoming clinical readouts in obesity and inflammatory disease as crucial. Despite some underperformance, growth prospects remain strong, with...

Via Benzinga

Why Amgen Stock Is Down Today Despite Solid Q2 Results ↗

August 07, 2024

Shares may have been likely to fall no matter what the company reported.

Via The Motley Fool

Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst ↗

August 07, 2024

Amgen reported a 20% year-over-year increase in second-quarter sales, reaching $8.39 billion, surpassing the $8.33 billion consensus. Guidance for 2024 includes adjusted EPS of $19.10-$20.10 and...

Via Benzinga

Amgen's MariTide Weight Loss Potential: Stock Outlook

August 07, 2024

Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.

Via MarketBeat

Topics Intellectual Property

Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday? ↗

August 07, 2024

The U.S.

Via Benzinga

AMGN Stock Earnings: Amgen Misses EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

AMGN stock results show that Amgen missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity' ↗

August 07, 2024

Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by...

Via Benzinga

Topics Stocks

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.